FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD
The Dermatology Digest
FEBRUARY 14, 2024
In addition, the European Medicines Agency has also accepted the Marketing Authorization Applications for nemolizumab in prurigo nodularis and atopic dermatitis. The European Medicines Agency has also accepted Galderma’s Marketing Authorization Applications for nemolizumab in both prurigo nodularis and atopic dermatitis.
Let's personalize your content